
Pfizer Inc.
PFE 27.16 (0.30%) 0.08
Health Care
Pharmaceuticals
Quality Checklist 3/8
Debt/Equity < 1
Current Ratio > 1
Net Margin > 10%
5Y Shares Out Change < 0%
ROIC > 10%
Quick Ratio > 1
Past Net Income CAGR > 0%
Est. EPS Growth > 5%
0.0%of Portfolio
My holdings
Day change:
Total change:
Shares:Cost basis:
Market cap: $154.42(B)
EV: $197.58(B)
Total Equity: $93.10(B)
Earnings date: Apr-28-2026
P/E: 19.82
Forward P/E: 9.18
P/FCF: 14.92
P/S: 2.47
P/B: 1.66
EPS: $1.4
EPS (fwd): $3.0
FCF/share: $1.8
Revenue/share: $11.0
Book value/share: $16.3
ROIC: 6.3%
ROA: 4.6%
ROE: 10.6%
Debt/Equity: 0.67
Current Ratio: 1.30
Gross margin: 75.8%
Operating margin: 24.6%
Net margin: 12.4%
Dividend/share: $1.7
Div. yield: 6.33%
PFE Valuation & Price Targets
Current Price
$27.2
Favorite Valuation Methods
More Valuation Methods
DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
DDM
N/A
N/A
EPS growth
N/A
N/A
Revenue growth
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A
PEvaluation
64% undervalued
Low
$33.3
Mid
$44.4
High
$55.5
Current price
$27.2
Fair P/E
Margin of safety
EPS
Market Model
Economic moat: Wide
EPS Estimates
| Low | Avg | High | # | |
| FY+1 | 2.8 | 3.0 | 3.2 | 26 |
| FY+2 | 2.5 | 2.8 | 3.0 | 25 |
| FY+3 | 2.0 | 2.4 | 2.9 | 16 |
| FY+4 | 1.7 | 2.1 | 2.7 | 10 |
| FY+5 | 1.5 | 2.1 | 2.9 | 10 |
Analyst Price Targets
1% overvalued
Low
$25.0
Mid
$27.0
High
$35.5
Current price
$27.2
Analyst Recommendations
2-stage DCF
First Stage Duration: 5 Years | |
| Starting Free Cash Flow | |
First Stage Growth Rate | |
LowMidHigh | |
Terminal Growth Rate | |
LowMidHigh | |
| Discount Rate | |
Discounted Cash Flow
Forecast years: 5 Years | |
Terminal Growth Rate | |
LowMidHigh | |
| Discount Rate | |
Free cash flow estimates:
Discounted Cash Flow (exit mult.)
Forecast years: 5 Years | |
Exit FCF Multiple | |
LowMidHigh | |
| Discount Rate | |
Free cash flow estimates:
Dividend Discount Model
| Annual Dividend | |
First Stage Length (Years): 0 Years | |
| First Stage Growth Rate | |
| Final Growth Rate | |
| Discount Rate | |
EPS Growth
Forecast years: 5 Years | |
| Starting EPS | |
EPS Growth Rate | |
LowMidHigh | |
Final P/E | |
LowMidHigh | |
| Discount Rate | |
Revenue Growth Valuation
Forecast Years: 10 Years | |
| Base Revenue | |
Revenue Growth Rate | |
LowMidHigh | |
Final Net Margin | |
LowMidHigh | |
Final P/E Ratio | |
LowMidHigh | |
| Discount Rate | |
Peter Lynch Fair Value
| Earnings Per Share | |
| Growth Rate |
Graham Formula
| Earnings Per Share | |
| EPS Growth (7-10 years) | |
| Government Bond Rate |
